CR7162A - AN A2A AGONIST IN COMBINATION WITH AN ANTI-POLINERGIC AGENT FOR THE TREATMENT OF AIRWAY OBSTRUCTIVE DISEASES - Google Patents

AN A2A AGONIST IN COMBINATION WITH AN ANTI-POLINERGIC AGENT FOR THE TREATMENT OF AIRWAY OBSTRUCTIVE DISEASES

Info

Publication number
CR7162A
CR7162A CR7162A CR7162A CR7162A CR 7162 A CR7162 A CR 7162A CR 7162 A CR7162 A CR 7162A CR 7162 A CR7162 A CR 7162A CR 7162 A CR7162 A CR 7162A
Authority
CR
Costa Rica
Prior art keywords
treatment
combination
agent
agonist
polinergic
Prior art date
Application number
CR7162A
Other languages
Spanish (es)
Inventor
A Armstrong Rosin
Yeadon Michael
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR7162A publication Critical patent/CR7162A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

se refiere a una combinacion de un agonista selectivo del receptor A2a de adenosina y un agente anticolinergico para la administracion simultanea, consecutiva o separada por via de inhalacion en el tratamiento de una enfermedad obstructiva de las vias aereas u otra enfermedad inflamatoria, con la condicion de que el agente anticolinergico no sea una sal de tiotropio.refers to a combination of a selective adenosine A2a receptor agonist and an anticholinergic agent for simultaneous, consecutive or separate administration by inhalation in the treatment of an obstructive airway disease or other inflammatory disease, with the condition of that the anticholinergic agent is not a tiotropium salt.

CR7162A 2001-05-25 2003-11-19 AN A2A AGONIST IN COMBINATION WITH AN ANTI-POLINERGIC AGENT FOR THE TREATMENT OF AIRWAY OBSTRUCTIVE DISEASES CR7162A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25

Publications (1)

Publication Number Publication Date
CR7162A true CR7162A (en) 2004-02-23

Family

ID=34572599

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7162A CR7162A (en) 2001-05-25 2003-11-19 AN A2A AGONIST IN COMBINATION WITH AN ANTI-POLINERGIC AGENT FOR THE TREATMENT OF AIRWAY OBSTRUCTIVE DISEASES

Country Status (4)

Country Link
CR (1) CR7162A (en)
EC (1) ECSP034863A (en)
PY (1) PY0212140A (en)
ZA (1) ZA200308465B (en)

Also Published As

Publication number Publication date
PY0212140A (en) 2004-07-01
ZA200308465B (en) 2004-11-01
ECSP034863A (en) 2004-01-28

Similar Documents

Publication Publication Date Title
PA8546101A1 (en) AN A2A ANTAGONIST IN COMBINATION WITH AN ANTI-POLINERGIC AGENT FOR THE TREATMENT OF OBSTRUCTIVE DISEASES OF THE AIRWAYS
CR7152A (en) A PDE4 INHIBITOR AND A COMBINATION ANTI-POLINERGIC AGENT TO TREAT OBSTRUCTIVE DISEASES OF RESPIRATORY ROADS.
BR0008039A (en) Combinations of formoterol and a tiotropium salt
BR0115910A (en) Organic compounds
MEP35308A (en) COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF
NO2014028I2 (en) Glucopyranosyl-substituted benzene derivatives, process for their preparation, physiologically acceptable salts of such compounds, drugs containing such compounds and combinations with other active substances, and their use in the manufacture of drugs for the treatment of disease
NO2013017I1 (en) (a) dextromethorphan or a pharmaceutically acceptable salt, precursor or derivative, for example, extromethorphan hydrobromide and especially dextromethorphan hydrobromide monohydrate; and (b) quinidine or a pharmaceutically acceptable salt, precursor or derivative thereof, for example quinidine and especially quinidine sulphate dihydrate
UY27532A1 (en) DOSAGE FORM OF DUAL CONTROLLED RELEASE.
CY1106430T1 (en) MEDICATIONS FOR INHALATION CONTAINING VITAMINS AND AN ANTICHOLINEPG
BR0307320A (en) Osmotic release system
CR7162A (en) AN A2A AGONIST IN COMBINATION WITH AN ANTI-POLINERGIC AGENT FOR THE TREATMENT OF AIRWAY OBSTRUCTIVE DISEASES
PY0228254A (en) PHARMACEUTICAL COMBINATION
UY27565A1 (en) PHARMACEUTICAL COMBINATION
AR044675A1 (en) METHOD FOR THE TREATMENT OF SCHIZOPHRENIA IN A PATIENT WITH OVERWEIGHT
BRPI0410374A (en) pharmaceutical composition comprising valsartan
UY27308A1 (en) AN A2A AGONIST IN COMBINATION WITH AN ANTI-POLYNERGIC AGENT FOR THE TREATMENT OF OBSTRUCTIVE DISEASES OF THE AIRWAYS
HN2002000128A (en) AN A2A AGONIST IN COMBINATION WITH AN ANTICHOLINERGIC AGENT FOR THE TREATMENT OF OBSTRUCTIVE DISEASES OF THE AIRWAYS.
UY27564A1 (en) PHARMACEUTICAL COMBINATION
DOP2002000514A (en) PHARMACEUTICAL COMBINATION
BRPI0517983A (en) corticosteroid use in combination with diuretic and antacid for treatment of vascular stenosis and prevention of vascular restenosis
BR112021026291A2 (en) Lemborexant to treat sleep problems
ECSP034864A (en) A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT IN COMBINATION TO TREAT OBSTRUCTIVE DISEASES OF RESPIRATORY ROADS
CO5590922A2 (en) USE OF ISTRADEFILINE (KW-6002) FOR THE TREATMENT OF CONDUCT DISORDERS
AR077846A1 (en) METHOD FOR DECREASING NASAL SYMPTOMS ASSOCIATED WITH NICOTINE ADMINISTRATION IN NASAL MUCOSA
Stasia Itraconazole/posaconazole

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)